Huizhen Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huizhen Sun has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Wei Chen
Zhongshan Hospital Fudan University
3 shared publicationsDongling Wu
Department of Obstetrics and Gynecology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, 200092 Shanghai, China
2 shared publications- Jin Zhao
Department of Gynecology, Changxing People's Hospital of Chongming District, Shanghai, China
2 shared publications Linlin Wang
Department of Gynecology, Changxing People's Hospital of Chongming District, Shanghai, China
2 shared publicationsMidie Xu
Fudan University Shanghai Cancer Center
2 shared publicationsNing Shao
Department of Gynecology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
2 shared publications
Latest Publications
- 6 March 2026
- p. 25056
RRM2/GCH1 signaling decreased cisplatin sensitivity in cervical cancer by modulating the ferroptosis process.
Cisplatin-based chemotherapy serves as a fundamental approach in the treatment of cervical cancer; however, its effectiveness is often hindered by the development of drug resistance, which presents a significant obstacle in clinical practice. Differentially expressed genes (DEGs) related to ferroptosis in cervical cancer were examined compared to healthy controls, using data from the Gene Expression Omnibus (GEO) database and the ferroptosis database (FerrDb V2). Lipid peroxidation, ferrous ion (Fe2+) concentration, and reactive oxygen species (ROS) were examined. In vitro and in vivo studies were carried out to explore the influence of Ribonucleotide reductase M2 (RRM2) on the effectiveness of cisplatin chemotherapy. We identified an aggregate of 4,385 statistically significant DEGs, among which 122 genes were related to ferroptosis. Moreover, the ferroptosis-related gene RRM2 was notably overexpressed in cervical cancer and demonstrated remarkable sensitivity and specificity for diagnosing cervical cancer. Additionally, the expression levels were inversely correlated with the outcomes of patients with cervical cancer. Furthermore, RRM2 silencing increased cervical cancer cell ferroptosis and enhanced the efficacy of cisplatin treatment in vitro and in vivo. Finally, our experiments established a positive association between RRM2 and the classical ferroptosis inhibition factor GTP cyclohydrolase 1 (GCH1) by immunofluorescence and immunoblotting. RRM2 plays roles in the evaluation and outcome prediction of cervical cancer, potentially impacting cisplatin sensitivity through regulation of ferroptosis. This investigation provides novel insights into the tumorigenic functions of RRM2, highlighting its potential use as a prognostic biomarker in cervical carcinoma.
- 6 March 2026
- p. 25056
RRM2/GCH1 signaling decreased cisplatin sensitivity in cervical cancer by modulating the ferroptosis process.
Cisplatin-based chemotherapy serves as a fundamental approach in the treatment of cervical cancer; however, its effectiveness is often hindered by the development of drug resistance, which presents a significant obstacle in clinical practice. Differentially expressed genes (DEGs) related to ferroptosis in cervical cancer were examined compared to healthy controls, using data from the Gene Expression Omnibus (GEO) database and the ferroptosis database (FerrDb V2). Lipid peroxidation, ferrous ion (Fe2+) concentration, and reactive oxygen species (ROS) were examined. In vitro and in vivo studies were carried out to explore the influence of Ribonucleotide reductase M2 (RRM2) on the effectiveness of cisplatin chemotherapy. We identified an aggregate of 4,385 statistically significant DEGs, among which 122 genes were related to ferroptosis. Moreover, the ferroptosis-related gene RRM2 was notably overexpressed in cervical cancer and demonstrated remarkable sensitivity and specificity for diagnosing cervical cancer. Additionally, the expression levels were inversely correlated with the outcomes of patients with cervical cancer. Furthermore, RRM2 silencing increased cervical cancer cell ferroptosis and enhanced the efficacy of cisplatin treatment in vitro and in vivo. Finally, our experiments established a positive association between RRM2 and the classical ferroptosis inhibition factor GTP cyclohydrolase 1 (GCH1) by immunofluorescence and immunoblotting. RRM2 plays roles in the evaluation and outcome prediction of cervical cancer, potentially impacting cisplatin sensitivity through regulation of ferroptosis. This investigation provides novel insights into the tumorigenic functions of RRM2, highlighting its potential use as a prognostic biomarker in cervical carcinoma.
- Open Access
- 1 January 2026
- Published by SAGE Publications in Science Progress
- Vol. 109 (1)
ULK2 suppresses glycolysis to attenuate cisplatin resistance in ovarian cancer organoid via c-Jun phosphorylation
Objective: Resistance to platinum-based chemotherapy remains a key obstacle in ovarian cancer treatment. This study aims to investigate the role of Uncoordinated 51-like kinase 2 (ULK2) in chemoresistance of ovarian cancer and elucidate its underlying mechanisms using 3D patient-derived organoids. Methods: Survival analysis was first performed using the Kaplan‒Meier plotter database. Immunohistochemical profiling delineated differential ULK2 expression patterns between chemoresistant and chemosensitive ovarian cancer tissue samples and organoids. ULK2 overexpression was achieved in cisplatin-resistant ovarian cancer organoids via lentiviral vector transduction. Then, we conducted an in-depth examination of the alterations in phosphorylated proteins induced by ULK2 overexpression using phosphoproteomics technology. To investigate the influence of ULK2 on chemosensitivity in ovarian cancer, Cell Counting Kit-8 (CCK-8) and in vivo experiments were conducted. Glycolysis was quantitatively assessed, and the underlying molecular mechanism was systematically investigated. Results: ULK2 high-expression ovarian cancer exhibited enhanced chemosensitivity and conferred survival advantage. CCK-8 and mouse experiments demonstrated that ULK2 overexpression decreased cisplatin resistance in patient-derived organoids. Gene Ontology (GO) analysis of phosphoproteomics profiling highlighted the predominant role of ULK2 in metabolic processes with experimental validation demonstrating its suppression of glycolysis. Mechanistically, ULK2 attenuated c-Jun expression by phosphorylation of c-Jun at Ser243. Moreover, c-Jun overexpression counteracted the chemosensitivity and glycolytic suppression induced by the ectopic ULK2 expression in ovarian cancer. Conclusions: ULK2 overcomes cisplatin resistance in ovarian cancer by downregulating glycolysis, a process mediated by phosphorylation-induced c-Jun degradation. These findings emphasized the role of ULK2 as a tumor suppressor, offering novel insights for chemotherapy in ovarian cancer.
- 1 January 2026
- Published by SAGE Publications in Science Progress
- Vol. 109 (1)
Open AccessULK2 suppresses glycolysis to attenuate cisplatin resistance in ovarian cancer organoid via c-Jun phosphorylation
Objective: Resistance to platinum-based chemotherapy remains a key obstacle in ovarian cancer treatment. This study aims to investigate the role of Uncoordinated 51-like kinase 2 (ULK2) in chemoresistance of ovarian cancer and elucidate its underlying mechanisms using 3D patient-derived organoids. Methods: Survival analysis was first performed using the Kaplan‒Meier plotter database. Immunohistochemical profiling delineated differential ULK2 expression patterns between chemoresistant and chemosensitive ovarian cancer tissue samples and organoids. ULK2 overexpression was achieved in cisplatin-resistant ovarian cancer organoids via lentiviral vector transduction. Then, we conducted an in-depth examination of the alterations in phosphorylated proteins induced by ULK2 overexpression using phosphoproteomics technology. To investigate the influence of ULK2 on chemosensitivity in ovarian cancer, Cell Counting Kit-8 (CCK-8) and in vivo experiments were conducted. Glycolysis was quantitatively assessed, and the underlying molecular mechanism was systematically investigated. Results: ULK2 high-expression ovarian cancer exhibited enhanced chemosensitivity and conferred survival advantage. CCK-8 and mouse experiments demonstrated that ULK2 overexpression decreased cisplatin resistance in patient-derived organoids. Gene Ontology (GO) analysis of phosphoproteomics profiling highlighted the predominant role of ULK2 in metabolic processes with experimental validation demonstrating its suppression of glycolysis. Mechanistically, ULK2 attenuated c-Jun expression by phosphorylation of c-Jun at Ser243. Moreover, c-Jun overexpression counteracted the chemosensitivity and glycolytic suppression induced by the ectopic ULK2 expression in ovarian cancer. Conclusions: ULK2 overcomes cisplatin resistance in ovarian cancer by downregulating glycolysis, a process mediated by phosphorylation-induced c-Jun degradation. These findings emphasized the role of ULK2 as a tumor suppressor, offering novel insights for chemotherapy in ovarian cancer.
- Open Access
- 1 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-16
Nuclear receptor subfamily 1 group D member 2 induces chemoresistance in ovarian cancer by regulating ferroptosis and immune infiltration
Ovarian cancer is known for its high recurrence rates and poor prognosis, primarily due to chemoresistance, which significantly limits treatment options. Grasping the processes that contribute to chemoresistance is essential for the advancement of more efficient therapy methods. Firstly, we discovered that nuclear receptor subfamily 1 group D member 2 (NR1D2) was significantly elevated in cisplatin-resistant ovarian cancer cells, as revealed by RNA sequencing. Subsequent study indicated that NR1D2 was highly expressed in chemo-resistant ovarian cancer samples than the chemo-sensitive group, and negatively correlated with ovarian cancer patients’ survival. Moreover, NR1D2 silencing markedly contributed to cisplatin susceptibility of ovarian cancer cells. Additionally, the analysis of untargeted metabolomics mass spectrometry demonstrated a significant correlation between NR1D2 and the process of ferroptosis. Following this, we observed that NR1D2 silencing considerably increased the concentration of lipid peroxidation malondialdehyde (MDA) and ferrous ion, concomitant with downregulation of ferroptosis suppressor protein 1 (FSP1). Finally, the study revealed that NR1D2 influences immune infiltration in ovarian cancer. In summary, NR1D2 served as a prognostic biomarker in ovarian cancer and induced cisplatin-resistance. Furthermore, its expression was linked to ferroptosis and immune regulation within the tumor microenvironment. Targeting NR1D2 may provide a potential therapeutic strategy to enhance treatment efficacy in ovarian cancer.
- 1 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-16
Open AccessNuclear receptor subfamily 1 group D member 2 induces chemoresistance in ovarian cancer by regulating ferroptosis and immune infiltration
Ovarian cancer is known for its high recurrence rates and poor prognosis, primarily due to chemoresistance, which significantly limits treatment options. Grasping the processes that contribute to chemoresistance is essential for the advancement of more efficient therapy methods. Firstly, we discovered that nuclear receptor subfamily 1 group D member 2 (NR1D2) was significantly elevated in cisplatin-resistant ovarian cancer cells, as revealed by RNA sequencing. Subsequent study indicated that NR1D2 was highly expressed in chemo-resistant ovarian cancer samples than the chemo-sensitive group, and negatively correlated with ovarian cancer patients’ survival. Moreover, NR1D2 silencing markedly contributed to cisplatin susceptibility of ovarian cancer cells. Additionally, the analysis of untargeted metabolomics mass spectrometry demonstrated a significant correlation between NR1D2 and the process of ferroptosis. Following this, we observed that NR1D2 silencing considerably increased the concentration of lipid peroxidation malondialdehyde (MDA) and ferrous ion, concomitant with downregulation of ferroptosis suppressor protein 1 (FSP1). Finally, the study revealed that NR1D2 influences immune infiltration in ovarian cancer. In summary, NR1D2 served as a prognostic biomarker in ovarian cancer and induced cisplatin-resistance. Furthermore, its expression was linked to ferroptosis and immune regulation within the tumor microenvironment. Targeting NR1D2 may provide a potential therapeutic strategy to enhance treatment efficacy in ovarian cancer.
- Open Access
- 25 September 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (19) , 19807-19820
TRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2‐mediated glycolysis
Ample evidence reveals that glycolysis is crucial to tumor progression; however, the underlying mechanism of its drug resistance is still worth being further explored. TRAF6, an E3 ubiquitin ligase, is well recognized to overexpress in various types of cancer, which predicts a poor prognosis. In our study, we discovered that TRAF6 was expressed more significantly in the case of triple‐negative breast cancer (TNBC) than in other of breast cancers, promoting chemoresistance to paclitaxel; that inhibited TRAF6 expression in the chemoresistant TNBC (TNBC‐CR) cells enhanced the sensitivity by decreasing glucose uptake and lactate production; that TRAF6 regulated glycolysis and facilitated chemoresistance via binding directly to PKM2; and that overexpressing PKM2 in the TNBC‐CR cells with TRAF6 knocked down regained significantly TRAF6‐dependent drug resistance and glycolysis. Additionally, we verified that TRAF6 could facilitate PKM2‐mediated glycolysis and chemoresistance in animal models and clinical tumor tissues. Thus, we identified the novel function of TRAF6 to promote glycolysis and drug resistance in TNBC with the regulation of PKM2, which could provide a potential molecular target for TNBC treatment.
- 25 September 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (19) , 19807-19820
Open AccessTRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2‐mediated glycolysis
Ample evidence reveals that glycolysis is crucial to tumor progression; however, the underlying mechanism of its drug resistance is still worth being further explored. TRAF6, an E3 ubiquitin ligase, is well recognized to overexpress in various types of cancer, which predicts a poor prognosis. In our study, we discovered that TRAF6 was expressed more significantly in the case of triple‐negative breast cancer (TNBC) than in other of breast cancers, promoting chemoresistance to paclitaxel; that inhibited TRAF6 expression in the chemoresistant TNBC (TNBC‐CR) cells enhanced the sensitivity by decreasing glucose uptake and lactate production; that TRAF6 regulated glycolysis and facilitated chemoresistance via binding directly to PKM2; and that overexpressing PKM2 in the TNBC‐CR cells with TRAF6 knocked down regained significantly TRAF6‐dependent drug resistance and glycolysis. Additionally, we verified that TRAF6 could facilitate PKM2‐mediated glycolysis and chemoresistance in animal models and clinical tumor tissues. Thus, we identified the novel function of TRAF6 to promote glycolysis and drug resistance in TNBC with the regulation of PKM2, which could provide a potential molecular target for TNBC treatment.
- Open Access
- 25 May 2023
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 28 (5) , 101
LRG1 Is Involved in the Progression of Ovarian Cancer via Modulating FAK/AKT Signaling Pathway
Background: Rapid progression and early metastasis remain the main cause of high mortality in epithelial ovarian cancer (EOC) patients. The objective of this study was to explore the mechanisms of EOC progression and detect the function of leucine-rich alpha-2-glycoprotein 1 (LRG1) in modulating the pathologic process. Methods: Ultracentrifugation was initially performed to extract exosomes from the urine samples of EOC patients and healthy female subjects. Mass spectrometry (MS) was employed to analyze differentially expressed proteins. Survival analysis was performed to examine the association between LRG1 levels and the prognosis of EOC patients. LRG1 silencing ovarian cancer cell lines were built and cell migration was further evaluated via wound healing and transwell assays. Immunoblot, immunofluorescence and immunohistochemistry analyses were performed. A subcutaneous tumor model was established to study the function of LRG1 in vivo. Results: Exosomal LRG1 was specifically expressed in urine samples of EOC patients and high LRG1 levels were significantly associated with poor prognosis. Function analyses showed that LRG1 was associated with ovarian cancer migration and progression. Mechanistically, LRG1 was significantly related to the focal adhesion kinase/protein kinase B (FAK/AKT) signaling pathway. Conclusions: LRG1 participated in progression and metastasis of ovarian cancer via activation of the FAK/AKT pathway probably.
- 25 May 2023
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 28 (5) , 101
Open AccessLRG1 Is Involved in the Progression of Ovarian Cancer via Modulating FAK/AKT Signaling Pathway
Background: Rapid progression and early metastasis remain the main cause of high mortality in epithelial ovarian cancer (EOC) patients. The objective of this study was to explore the mechanisms of EOC progression and detect the function of leucine-rich alpha-2-glycoprotein 1 (LRG1) in modulating the pathologic process. Methods: Ultracentrifugation was initially performed to extract exosomes from the urine samples of EOC patients and healthy female subjects. Mass spectrometry (MS) was employed to analyze differentially expressed proteins. Survival analysis was performed to examine the association between LRG1 levels and the prognosis of EOC patients. LRG1 silencing ovarian cancer cell lines were built and cell migration was further evaluated via wound healing and transwell assays. Immunoblot, immunofluorescence and immunohistochemistry analyses were performed. A subcutaneous tumor model was established to study the function of LRG1 in vivo. Results: Exosomal LRG1 was specifically expressed in urine samples of EOC patients and high LRG1 levels were significantly associated with poor prognosis. Function analyses showed that LRG1 was associated with ovarian cancer migration and progression. Mechanistically, LRG1 was significantly related to the focal adhesion kinase/protein kinase B (FAK/AKT) signaling pathway. Conclusions: LRG1 participated in progression and metastasis of ovarian cancer via activation of the FAK/AKT pathway probably.
- Top Cited PapersOpen Access
- 2 March 2022
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 42 (3) , 245-265
The Fibrillin‐1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells
Background: Chemotherapy resistance is a primary reason of ovarian cancer therapy failure; hence it is important to investigate the underlying mechanisms of chemotherapy resistance and develop novel potential therapeutic targets. Methods: RNA sequencing of cisplatin‐resistant and ‐sensitive (chemoresistant and chemosensitive, respectively) ovarian cancer organoids was performed, followed by detection of the expression level of fibrillin‐1 (FBN1) in organoids and clinical specimens of ovarian cancer. Subsequently, glucose metabolism, angiogenesis, and chemosensitivity were analyzed in structural glycoprotein FBN1‐knockout cisplatin‐resistant ovarian cancer organoids and cell lines. To gain insights into the specific functions and mechanisms of action of FBN1 in ovarian cancer, immunoprecipitation, silver nitrate staining, mass spectrometry, immunofluorescence, Western blotting, and Fӧrster resonance energy transfer‐fluorescence lifetime imaging analyses were performed, followed by in vivo assays using vertebrate model systems of nude mice and zebrafish. Results: FBN1 expression was significantly enhanced in cisplatin‐resistant ovarian cancer organoids and tissues, indicating that FBN1 might be a key factor in chemoresistance of ovarian cancer. We also discovered that FBN1 sustained the energy stress and induced angiogenesis in vitro and in vivo, which promoted the cisplatin‐resistance of ovarian cancer. Knockout of FBN1 combined with treatment of the antiangiogenic drug apatinib improved the cisplatin‐sensitivity of ovarian cancer cells. Mechanistically, FBN1 mediated the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2) at the Tyr1054 residue, which activated its downstream focal adhesion kinase (FAK)/protein kinase B (PKB or AKT) pathway, induced the phosphorylation of signal transducer and activator of transcription 2 (STAT2) at the tyrosine residue 690 (Tyr690), promoted the nuclear translocation of STAT2, and ultimately altered the expression of genes associated with STAT2‐mediated angiogenesis and glycolysis. Conclusions: The FBN1/VEGFR2/STAT2 signaling axis may induce chemoresistance of ovarian cancer cells by participating in the process of glycolysis and angiogenesis. The present study suggested a novel FBN1‐targeted therapy and/or combination of FBN1 inhibition and antiangiogenic drug for treating ovarian cancer.
- 2 March 2022
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 42 (3) , 245-265
Top Cited PapersOpen AccessThe Fibrillin‐1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells
Background: Chemotherapy resistance is a primary reason of ovarian cancer therapy failure; hence it is important to investigate the underlying mechanisms of chemotherapy resistance and develop novel potential therapeutic targets. Methods: RNA sequencing of cisplatin‐resistant and ‐sensitive (chemoresistant and chemosensitive, respectively) ovarian cancer organoids was performed, followed by detection of the expression level of fibrillin‐1 (FBN1) in organoids and clinical specimens of ovarian cancer. Subsequently, glucose metabolism, angiogenesis, and chemosensitivity were analyzed in structural glycoprotein FBN1‐knockout cisplatin‐resistant ovarian cancer organoids and cell lines. To gain insights into the specific functions and mechanisms of action of FBN1 in ovarian cancer, immunoprecipitation, silver nitrate staining, mass spectrometry, immunofluorescence, Western blotting, and Fӧrster resonance energy transfer‐fluorescence lifetime imaging analyses were performed, followed by in vivo assays using vertebrate model systems of nude mice and zebrafish. Results: FBN1 expression was significantly enhanced in cisplatin‐resistant ovarian cancer organoids and tissues, indicating that FBN1 might be a key factor in chemoresistance of ovarian cancer. We also discovered that FBN1 sustained the energy stress and induced angiogenesis in vitro and in vivo, which promoted the cisplatin‐resistance of ovarian cancer. Knockout of FBN1 combined with treatment of the antiangiogenic drug apatinib improved the cisplatin‐sensitivity of ovarian cancer cells. Mechanistically, FBN1 mediated the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2) at the Tyr1054 residue, which activated its downstream focal adhesion kinase (FAK)/protein kinase B (PKB or AKT) pathway, induced the phosphorylation of signal transducer and activator of transcription 2 (STAT2) at the tyrosine residue 690 (Tyr690), promoted the nuclear translocation of STAT2, and ultimately altered the expression of genes associated with STAT2‐mediated angiogenesis and glycolysis. Conclusions: The FBN1/VEGFR2/STAT2 signaling axis may induce chemoresistance of ovarian cancer cells by participating in the process of glycolysis and angiogenesis. The present study suggested a novel FBN1‐targeted therapy and/or combination of FBN1 inhibition and antiangiogenic drug for treating ovarian cancer.
- Open Access
- 5 October 2021
- Published by Springer Nature in Research Square
OCT4 Promotes Ovarian Cancer Cell Metastasis and Angiogenesis via Modulating VEGFR2/LRPPRC Pathway
Background: Due to its high ability of metastasis, ovarian cancer remains the most lethal gynecological malignancy, yet its underlying mechanism remains unconfirmed. Objectives: The main purpose is to probe into the role and regulation mechanism of octamer-binding transcription factor 4 (OCT4) in angiogenesis and metastasis in ovarian cancer.Methods: Immunohistochemistry (IHC) and immunofluorescence in epithelial ovarian cancer specimens and benign ovarian tumor samples were performed, followed by RNA-sequencing and examination of angiogenesis, cell migration and invasion in OCT4 knockdown cell lines and the controls. Co-Immunoprecipitation (Co-IP), mass spectrometry, immunoblotting, immunofluorescence and chromatin immunoprecipitation (ChIP) analyses were conducted along with models of zebrafishes and nude mice of transplanted tumors to gain insights into the specific functions and mechanisms of action of OCT4 in ovarian cancer.Results: Firstly, we discovered that OCT4 expression was enhanced in ovarian cancer tissues significantly, especially in the metastatic lesions, indicating that OCT4 might be a key for the metastasis of ovarian cancer. Furtherly, we observed and verified that OCT4 promoted cell migration and invasion, and induced angiogenesis in vitro and in vivo. Mechanistically, OCT4 modulated the transcription of leucine‑rich PPR motif‑containing protein (LRPPRC),and furtherly interacted with vascular endothelial growth factor receptor 2 (VEGFR2)/LRPPRC complex and ultimately triggered the downstream FAK/AKT signaling pathway . Conclusions: Together, through models of ovarian cancer cells, zebrafishes and tumor-transplanted mice, this study highlighted the importance of OCT4/LRPPRC/VEGFR2 signaling axis in metastasis of ovarian cancer and angiogenesis. Thus, our finding supplied a potential novel molecular-targeted approach for the treatment of ovarian cancer.
- 5 October 2021
- Published by Springer Nature in Research Square
Open AccessOCT4 Promotes Ovarian Cancer Cell Metastasis and Angiogenesis via Modulating VEGFR2/LRPPRC Pathway
Background: Due to its high ability of metastasis, ovarian cancer remains the most lethal gynecological malignancy, yet its underlying mechanism remains unconfirmed. Objectives: The main purpose is to probe into the role and regulation mechanism of octamer-binding transcription factor 4 (OCT4) in angiogenesis and metastasis in ovarian cancer.Methods: Immunohistochemistry (IHC) and immunofluorescence in epithelial ovarian cancer specimens and benign ovarian tumor samples were performed, followed by RNA-sequencing and examination of angiogenesis, cell migration and invasion in OCT4 knockdown cell lines and the controls. Co-Immunoprecipitation (Co-IP), mass spectrometry, immunoblotting, immunofluorescence and chromatin immunoprecipitation (ChIP) analyses were conducted along with models of zebrafishes and nude mice of transplanted tumors to gain insights into the specific functions and mechanisms of action of OCT4 in ovarian cancer.Results: Firstly, we discovered that OCT4 expression was enhanced in ovarian cancer tissues significantly, especially in the metastatic lesions, indicating that OCT4 might be a key for the metastasis of ovarian cancer. Furtherly, we observed and verified that OCT4 promoted cell migration and invasion, and induced angiogenesis in vitro and in vivo. Mechanistically, OCT4 modulated the transcription of leucine‑rich PPR motif‑containing protein (LRPPRC),and furtherly interacted with vascular endothelial growth factor receptor 2 (VEGFR2)/LRPPRC complex and ultimately triggered the downstream FAK/AKT signaling pathway . Conclusions: Together, through models of ovarian cancer cells, zebrafishes and tumor-transplanted mice, this study highlighted the importance of OCT4/LRPPRC/VEGFR2 signaling axis in metastasis of ovarian cancer and angiogenesis. Thus, our finding supplied a potential novel molecular-targeted approach for the treatment of ovarian cancer.
- Open Access
- 3 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 41 (6) , 511-527
Programmed death ligand‐1 regulates angiogenesis and metastasis by participating in the c‐JUN/VEGFR2 signaling axis in ovarian cancer
Background: Although programmed cell death‐ligand 1 (PD‐L1) plays a well‐known function in immune checkpoint response by interacting with programmed cell death‐1 (PD‐1), the cell‐intrinsic role of PD‐L1 in tumors is still unclear. Here, we explored the molecular regulatory mechanism of PD‐L1 in the progression and metastasis of ovarian cancer. Methods: Immunohistochemistry of benign tissues and ovarian cancer samples was performed, followed by migration, invasion, and angiogenesis assays in PD‐L1‐knockdown ovarian cancer cells. Immunoprecipitation, mass spectrometry, and chromatin immunoprecipitation were conducted along with zebrafish and mouse experiments to explore the specific functions and mechanisms of PD‐L1 in ovarian cancer. Results: Our results showed that PD‐L1 induced angiogenesis, which further promoted cell migration and invasion in vitro and in vivo of ovarian cancer. Mechanistically, PD‐L1 was identified to directly interact with vascular endothelial growth factor receptor‐2 (VEGFR2) and then activated the FAK/AKT pathway, which further induced angiogenesis and tumor progression, leading to poor prognosis of ovarian cancer patients. Meanwhile, PD‐L1 was found to be regulated by the oncogenic transcription factor c‐JUN at the transcriptional level, which enhanced the expression of PD‐L1 in ovarian cancer. Furthermore, we demonstrated that PD‐L1 inhibitor durvalumab, combined with the antiangiogenic drug, apatinib, could enhance the effect of anti‐angiogenesis and the inhibition of cell migration and invasion. Conclusion: Our results demonstrated that PD‐L1 promoted the angiogenesis and metastasis of ovarian cancer by participating in the c‐JUN/VEGFR2 signaling axis, suggesting that the combination of PD‐L1 inhibitor and antiangiogenic drugs may be considered as a potential therapeutic approach for ovarian cancer patients.
- 3 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 41 (6) , 511-527
Open AccessProgrammed death ligand‐1 regulates angiogenesis and metastasis by participating in the c‐JUN/VEGFR2 signaling axis in ovarian cancer
Background: Although programmed cell death‐ligand 1 (PD‐L1) plays a well‐known function in immune checkpoint response by interacting with programmed cell death‐1 (PD‐1), the cell‐intrinsic role of PD‐L1 in tumors is still unclear. Here, we explored the molecular regulatory mechanism of PD‐L1 in the progression and metastasis of ovarian cancer. Methods: Immunohistochemistry of benign tissues and ovarian cancer samples was performed, followed by migration, invasion, and angiogenesis assays in PD‐L1‐knockdown ovarian cancer cells. Immunoprecipitation, mass spectrometry, and chromatin immunoprecipitation were conducted along with zebrafish and mouse experiments to explore the specific functions and mechanisms of PD‐L1 in ovarian cancer. Results: Our results showed that PD‐L1 induced angiogenesis, which further promoted cell migration and invasion in vitro and in vivo of ovarian cancer. Mechanistically, PD‐L1 was identified to directly interact with vascular endothelial growth factor receptor‐2 (VEGFR2) and then activated the FAK/AKT pathway, which further induced angiogenesis and tumor progression, leading to poor prognosis of ovarian cancer patients. Meanwhile, PD‐L1 was found to be regulated by the oncogenic transcription factor c‐JUN at the transcriptional level, which enhanced the expression of PD‐L1 in ovarian cancer. Furthermore, we demonstrated that PD‐L1 inhibitor durvalumab, combined with the antiangiogenic drug, apatinib, could enhance the effect of anti‐angiogenesis and the inhibition of cell migration and invasion. Conclusion: Our results demonstrated that PD‐L1 promoted the angiogenesis and metastasis of ovarian cancer by participating in the c‐JUN/VEGFR2 signaling axis, suggesting that the combination of PD‐L1 inhibitor and antiangiogenic drugs may be considered as a potential therapeutic approach for ovarian cancer patients.